News | September 02, 2008

Study Shows DES Improves Survivial in STEMI Patients

September 2, 2008 - The safety debate about drug-eluting stents (DES) is still ongoing and in these times of uncertainty about DES safety, a new study has shown DES markedly improves long-term survival, compared to modern bare-metal stents (BMS) in patients with acute ST-segment elevation myocardial infarction (STEMI).

Dr. Thorsten Grumann, of the University of Freiburg Department of Cardiology in Germany, explained the results of his study at the European Society of Cardiology 2008 Congress today. He said in the four-year investigation, DES demonstrated a significant reduction of mortality in this sick patient subset.
The study sought to present a subgroup analysis of patients with myocardial infarction followed long-term for a mean of four years in the Freiberg Stent Registry (FRIST), a single-centre registry in high volume tertiary referral cardiovascular centre. FRIST included complex coronary patients treated with DES and BMS in the University Hospital of Freiburg, Germany, according to nonselected inclusion criteria. For the first time, three drug eluting stents, namely Cypher, Taxus and Endeavor, were compared. The DES-groups were matched to a historical, contemporary BMS control group.

The primary study endpoint was overall survival. Cardiac and noncardiac death was also analyzed.

“We observed a significant survival benefit of patients who received DES compared with patients who received BMS in FRIST,” Dr. Grumann said.

The overall crude incidence for all-cause death was 7 percent (13 out of 186) in the DES-group and 24 percent (27 out of 112) in the BMS-group. Applying a multivariate Cox survival model with adjustment for existing baseline differences between the patient groups resulted in a relative risk of 0.42. That implies a 58 percent decrease of mortality risk in the DES population within the four-year observation period. The adjusted risk reduction with respect to cardiac death (-70 percent) was even more impressive. A number needed to treat analysis (NNT) looking at mortality indicated that if 30 patients were treated with a DES instead of a BMS in STEMI, one life could be saved.

“The analysis clearly favors DES implantation with a marked long term survival benefit in patients with myocardial infarction over BMS,” said Dr. Grumann.

Reduced total mortality for DES as compared to BMS, and a further reduction with respect to cardiac death suggests many patients can profit from “off-label” use of DES. Dr. Grumann said the registry shows for the first time that DES are not only equal, but superior to BMS when long-term survival is the primary concern in patients with STEMI. The data supports the TYPHOON-results but should be interpreted with caution until further randomized mortality trials have substantiated the reported findings.

For more information: thorsten.grumann@uniklinik-freiburg.de

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init